GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (OSTO:ONCOZ) » Definitions » EV-to-EBITDA

OncoZenge AB (OSTO:ONCOZ) EV-to-EBITDA : -1.50 (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, OncoZenge AB's enterprise value is kr21.36 Mil. OncoZenge AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-14.22 Mil. Therefore, OncoZenge AB's EV-to-EBITDA for today is -1.50.

The historical rank and industry rank for OncoZenge AB's EV-to-EBITDA or its related term are showing as below:

OSTO:ONCOZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.43   Med: 0   Max: 7.03
Current: -1.49

During the past 4 years, the highest EV-to-EBITDA of OncoZenge AB was 7.03. The lowest was -4.43. And the median was 0.00.

OSTO:ONCOZ's EV-to-EBITDA is ranked worse than
100% of 449 companies
in the Biotechnology industry
Industry Median: 9.42 vs OSTO:ONCOZ: -1.49

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-07), OncoZenge AB's stock price is kr3.55. OncoZenge AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-1.211. Therefore, OncoZenge AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


OncoZenge AB EV-to-EBITDA Historical Data

The historical data trend for OncoZenge AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB EV-to-EBITDA Chart

OncoZenge AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- -17.20 -1.73 -1.48

OncoZenge AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.37 8.24 2.66 -1.48 -2.12

Competitive Comparison of OncoZenge AB's EV-to-EBITDA

For the Biotechnology subindustry, OncoZenge AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoZenge AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's EV-to-EBITDA falls into.



OncoZenge AB EV-to-EBITDA Calculation

OncoZenge AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=21.363/-14.221
=-1.50

OncoZenge AB's current Enterprise Value is kr21.36 Mil.
OncoZenge AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-14.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoZenge AB  (OSTO:ONCOZ) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

OncoZenge AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.55/-1.211
=At Loss

OncoZenge AB's share price for today is kr3.55.
OncoZenge AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.211.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


OncoZenge AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoZenge AB (OSTO:ONCOZ) Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB (OSTO:ONCOZ) Headlines

No Headlines